



Universiteit
Leiden
The Netherlands

Clinical characteristics of human platelet antigen (HPA)-1a and HPA-5b alloimmunised pregnancies and the association between platelet HPA-5b antibodies and symptomatic fetal neonatal alloimmune thrombocytopenia (vol 195, pg 595, 2021)

Vos, T.W.; Porcelijn, L.; Hofstede-van Egmond, S.; Pajkrt, E.; Oepkes, D.; Lopriore, E.; ... ; Haas, M. de

Citation

Vos, T. W., Porcelijn, L., Hofstede-van Egmond, S., Pajkrt, E., Oepkes, D., Lopriore, E., ... Haas, M. de. (2022). Clinical characteristics of human platelet antigen (HPA)-1a and HPA-5b alloimmunised pregnancies and the association between platelet HPA-5b antibodies and symptomatic fetal neonatal alloimmune thrombocytopenia (vol 195, pg 595, 2021). *British Journal Of Haematology*, 196(6), 1412-1413. doi:10.1111/bjh.18107

Version: Publisher's Version
License: [Leiden University Non-exclusive license](#)
Downloaded from: <https://hdl.handle.net/1887/3566397>

Note: To cite this publication please use the final published version (if applicable).

ERRATUM

This article corrects the following:

de Vos TW, Porcelijn L, Hofstede-van Egmond S, Pajkrt E, Oepkes D, Lopriore E, van der Schoot CE, Winkelhorst D, de Haas M. Clinical characteristics of human platelet antigen (HPA)-1a and HPA-5b alloimmunised pregnancies and the association between platelet HPA-5b antibodies and symptomatic fetal neonatal alloimmune thrombocytopenia. *Br J Haematol* 2021; 195: 595–603. <https://doi.org/10.1111/bjh.17731>

In the article by de Vos et al. (2021), the figure legends of Figures 1 and 2 are incomplete.

The corrected figure legends of Figures 1 and 2 are as follows:




FIGURE 1 Flowchart study population. FNAIT, fetal neonatal alloimmune thrombocytopenia; HPA, Human platelet antigen




FIGURE 2 Platelet count and clinical outcome. HPA, Human platelet antigen; IVIg, intravenous immune globulins; Black lines represent median value per group, medians were calculated including cases that were not treated antenatally with IVIg. # Missing values for 4 cases due to mortality. ¶ Missing values for 1 case due to mortality, 2 cases were treated with IVIg during pregnancy (open dots). ‡ Missing values for 2 cases, 1 case was treated with IVIg during pregnancy (open dot, black border). Φ Antenatal IVIg treatment was applied in 9 pregnancies (open dots) of which one case with platelet count $364 \times 10^9/l$ not shown [Colour figure can be viewed at wileyonlinelibrary.com]

We apologise for this error. The original article in the online version has been updated.